A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution
Background: Epirubicin is an anthracycline antineoplastic drug that is primarily used in combination therapies for the treatment of breast, gastric, lung and ovarian cancers and lymphomas. Epirubicin is administered intravenously (IV) over 3 to 5 min once every 21 days with dosing based on body surf...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2023-04-01
|
| Col·lecció: | Pharmaceutics |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1999-4923/15/4/1222 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|